Please ensure Javascript is enabled for purposes of website accessibility

West Bank Town Becomes ‘Big Prison’ as Israel Fences It In

12 hours ago

Trump Says He’s Willing to Let Migrant Farm Laborers Stay in US

12 hours ago

US Electric Vehicle Tax Breaks Will Expire on Sept. 30

1 day ago

Eyeing Arctic Dominance, Trump Bill Earmarks $8.6 Billion for US Coast Guard Icebreakers

1 day ago

Trump’s Sweeping Tax-Cut and Spending Bill Wins Congressional Approval

1 day ago

Americans Celebrate Their Independence With Record-Breaking Travel Numbers

1 day ago

US Supreme Court to Decide Legality of Transgender School Sports Bans

2 days ago

Nvidia Set to Become the World’s Most Valuable Company in History

2 days ago

Poll: 41% in US ‘Extremely Proud’ to Be American, Near Historic Low

2 days ago
FDA Allows Emergency Use of Remdesivir for Coronavirus
gvw_ap_news
By Associated Press
Published 5 years ago on
May 1, 2020

Share

WASHINGTON — U.S. regulators on Friday allowed emergency use of an experimental drug that appears to help some coronavirus patients recover faster.

It is the first drug shown to help fight COVID-19, which has killed more than 230,000 people worldwide.

The FDA said in a statement that Gilead Science’s intravenous drug would be specifically indicated for hospitalized patients with “severe disease,” such as those experiencing breathing problems requiring supplemental oxygen or ventilators.

The study of 1,063 patients is the largest and most strict test of the drug and included a comparison group that received just usual care so remdesivir’s effects could be rigorously evaluated.

President Donald Trump announced the news at the White House alongside Gilead CEO Daniel O’Day and Food and Drug Administration Commissioner Stephen Hahn.

The FDA acted after preliminary results from a government-sponsored study showed that the drug, remdesivir, shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.

The study of 1,063 patients is the largest and most strict test of the drug and included a comparison group that received just usual care so remdesivir’s effects could be rigorously evaluated.

Those given the drug were able to leave the hospital in 11 days on average vs. 15 days for the comparison group.

The FDA said that performance warranted Friday’s decision, though regulators acknowledged “there is limited information known about the safety and effectiveness of using remdesivir.”

The drug’s side effects include potential inflammation of the liver and problems related to its infusion, which could lead to nausea, vomiting, sweating and low blood pressure. Fact sheets about dosing and potential safety issues will be provided to physicians and patients, the FDA said.

The National Institutes of Health’s Dr. Anthony Fauci said Wednesday the drug would become a new standard of care for severely ill COVID-19 patients. The drug, which blocks an enzyme the virus uses to copy its genetic material, has not been tested on people with milder illness.

The FDA authorized the drug under its emergency powers to quickly speed experimental drugs, tests and other medical products to patients during public health crises.

Remdesivir Will Still Need Formal Approval

In normal times the FDA requires “substantial evidence” of a drug’s safety and effectiveness, usually through one or more large, rigorously controlled patient studies. But during public health emergencies the agency can waive those standards, simply requiring that an experimental drug’s potential benefits outweigh its risks.

Gilead has said it would donate its currently available stock of the drug and is ramping up production to make more. It said the U.S. government would coordinate distribution of remdesivir to places most in need of it.

No drugs are approved now for treating the coronavirus, and remdesivir will still need formal approval.

The FDA can convert the drug’s status to full approval if Gilead or other researchers provide additional data of remdesivir’s safety and effectiveness.

“This is a very, very early stage so you wouldn’t expect to have any sort of full approval at this point,” said Cathy Burgess, an attorney specializing in FDA issues. “But obviously they want to get this out to patients as quickly as possible.”

The FDA previously allowed narrow use of a malaria drug, hydroxychloroquine, for hospitalized patients who were unable to take part in ongoing studies of the medication. Trump repeatedly promoted it as a possible COVID-19 treatment, but no large high-quality studies have shown the drug to work for that and it has significant safety concerns.

The FDA warned doctors late last month against prescribing the drug outside of hospital or research settings, due to risks of sometimes fatal heart side effects.

Two small studies published Friday add to concerns about the malaria drug. Critically ill COVID-19 patients given hydroxychloroquine were prone to heart rhythm problems, and for many risks mounted when it was combined with an antibiotic, the studies found.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Trump to Sign Tax-Cut and Spending Bill in July 4 Ceremony

DON'T MISS

Madre Fire Spurs Evacuations Across 3 Counties, Grows to More Than 70,000 Acres

DON'T MISS

Clovis, Sanger, Madera, and Bass Lake Will Light the Sky With Fireworks Shows Tonight

DON'T MISS

Oil Dips Ahead of Expected OPEC+ Output Increase

DON'T MISS

613 Killed at Gaza Aid Distribution Sites, Near Humanitarian Covoys, Says UN

DON'T MISS

Fresno County Authorities Investigating Suspicious Death of Transient Man

DON'T MISS

West Bank Town Becomes ‘Big Prison’ as Israel Fences It In

DON'T MISS

Israeli Military Kills 20 in Gaza as Trump Awaits Hamas Reply to Truce Proposal

DON'T MISS

Valley Crime Stoppers’ Most Wanted Person of the Day: Rachelle Maria Blanco

DON'T MISS

Russia Pounds Kyiv With Largest Drone Attack, Hours After Trump-Putin Call

UP NEXT

After Record Democratic Speech, House Republicans Begin Final Vote on Trump Tax-Cut Bill

UP NEXT

Americans Celebrate Their Independence With Record-Breaking Travel Numbers

UP NEXT

Poll: 41% in US ‘Extremely Proud’ to Be American, Near Historic Low

UP NEXT

Wired Wednesday: Why Is State Lawmaker Taking Aim at Rooftop Solar?

UP NEXT

Poorest Americans Dealt Biggest Blow Under Senate Republican Tax Package

UP NEXT

Check Out Newest Downtown Mural. It’s a Spectacular Tribute to Fresno Artisans

UP NEXT

Bryan Kohberger to Plead Guilty to Murders of Four Idaho Students

UP NEXT

Ukraine Voices Concern as US Halts Some Missile Shipments

UP NEXT

Poll: Most Americans Say National Divide, Political Violence Threaten Democracy

UP NEXT

Paramount Settles With Trump Over ‘60 Minutes’ Interview for $16 Million

Oil Dips Ahead of Expected OPEC+ Output Increase

11 hours ago

613 Killed at Gaza Aid Distribution Sites, Near Humanitarian Covoys, Says UN

11 hours ago

Fresno County Authorities Investigating Suspicious Death of Transient Man

11 hours ago

West Bank Town Becomes ‘Big Prison’ as Israel Fences It In

12 hours ago

Israeli Military Kills 20 in Gaza as Trump Awaits Hamas Reply to Truce Proposal

12 hours ago

Valley Crime Stoppers’ Most Wanted Person of the Day: Rachelle Maria Blanco

12 hours ago

Russia Pounds Kyiv With Largest Drone Attack, Hours After Trump-Putin Call

12 hours ago

Boxer Chavez Jr Expected to Be Deported to Mexico to Serve Sentence, Mexican President Says

12 hours ago

Markets’ 90-Day Tariff Pause Rollercoaster Nears an Uncertain End

12 hours ago

Trump Says He’s Willing to Let Migrant Farm Laborers Stay in US

12 hours ago

Trump to Sign Tax-Cut and Spending Bill in July 4 Ceremony

President Donald Trump is scheduled to sign a massive package of tax and spending cuts into law at a ceremony at the White House on Friday, ...

10 hours ago

President Donald Trump speaks during a press conference in the Roosevelt Room at the White House in Washington, D.C., U.S., May 12, 2025. (Reuters File)
10 hours ago

Trump to Sign Tax-Cut and Spending Bill in July 4 Ceremony

The Madre Fire burning near New Cuyama has scorched 70,801 acres as of Friday, July 4, 2025, afternoon, making it California’s largest wildfire of the year, with only 10% containment and multiple evacuation zones in place. (CalFire)
10 hours ago

Madre Fire Spurs Evacuations Across 3 Counties, Grows to More Than 70,000 Acres

11 hours ago

Clovis, Sanger, Madera, and Bass Lake Will Light the Sky With Fireworks Shows Tonight

A pumpjack operates at the Vermilion Energy site in Trigueres, France, June 14, 2024. (Reuters File)
11 hours ago

Oil Dips Ahead of Expected OPEC+ Output Increase

Palestinians gather to collect what remains of relief supplies from the distribution center of the U.S.-backed Gaza Humanitarian Foundation, in Rafah, in the southern Gaza Strip, June 5, 2025. (Reuters File)
11 hours ago

613 Killed at Gaza Aid Distribution Sites, Near Humanitarian Covoys, Says UN

Billy Wayne Sinisgalli, a 54-year-old transient known locally as Wayne, was found dead along a rural Fresno road Wednesday in what authorities are investigating as a suspicious death. (Fresno County SO)
11 hours ago

Fresno County Authorities Investigating Suspicious Death of Transient Man

Israel Builds a Fence Around the West Bank
12 hours ago

West Bank Town Becomes ‘Big Prison’ as Israel Fences It In

A view of the site of Thursday's Israeli strike that damaged and destroyed residential buildings, at Shati (Beach) refugee camp, in Gaza City, July 4, 2025. (Reuters/Mahmoud Issa)
12 hours ago

Israeli Military Kills 20 in Gaza as Trump Awaits Hamas Reply to Truce Proposal

Help continue the work that gets you the news that matters most.

Search

Send this to a friend